ADAM8 as a drug target in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with less than 5% survivors after 5 years. High expression levels of ADAM8, a metalloprotease-disintegrin, are correlated with poor clinical outcome. We show that ADAM8 expression is associated with increased migration and invasiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlomann, Uwe, Koller, Garrit, Conrad, Catharina, Ferdous, Taheera, Golfi, Panagiota, Garcia, Adolfo Molejon, Höfling, Sabrina, Parsons, Maddy, Costa, Patricia, Soper, Robin, Bossard, Maud, Hagemann, Thorsten, Roshani, Rozita, Sewald, Norbert, Ketchem, Randal R., Moss, Marcia L., Rasmussen, Fred H., Miller, Miles A., Lauffenburger, Douglas A., Tuveson, David A., Nimsky, Christopher, Bartsch, Jörg W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014123/
https://www.ncbi.nlm.nih.gov/pubmed/25629724
http://dx.doi.org/10.1038/ncomms7175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014123/
https://www.ncbi.nlm.nih.gov/pubmed/25629724
http://dx.doi.org/10.1038/ncomms7175

Ejemplares similares